Zentalis Pharmaceuticals
San Diego, California, United States · Biotechnology, Healthcare, Medical
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clini
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 170
- Industries
- Biotechnology, Healthcare, Medical
- Status
- Public (ZNTL)
- Website
- http://zentalis.com
- Company page
Recent activity at Zentalis Pharmaceuticals
- : SEC 8-K (7.01): On May 21, 2026, Zentalis Pharmaceuticals, Inc. issued a press release reporting important corporate updates which may be of interest to security holders. The specific contents of the release are detailed in Exhibit 99.1 attached to the filing. This Regulation FD Disclosure serves to inform investors and the public about significant developments within the company that occurred on the same date, maximizing transparency and compliance with the disclosure requirements set by the SEC.
- : SEC 8-K (7.01): On May 5, 2026, Zentalis Pharmaceuticals, Inc. issued a press release regarding significant corporate updates. This Regulation FD disclosure includes information intended for investment community transparency. The details of the press release highlight recent developments within the company, including possible initiatives, research advancements, or financial guidance. As this event occurred on the same day it was reported, it is timely and relevant for investors and stakeholders.
- : SEC 8-K (5.02): On December 15, 2025, Karan Takhar resigned from his position as a member of the Board of Directors of Zentalis Pharmaceuticals, Inc. and from all committees he served on. His resignation was effective immediately and did not result from any disagreements on operational matters with the Company. Following this change, the size of the Board of Directors was reduced from seven to six members. This change reflects an adjustment in the company's governance structure.
- : Zentalis Pharmaceuticals Appoints Jim Bucher as Chief Legal Officer
- : Zentalis Pharmaceuticals Appoints New CEO and Chief Medical Officer
- : Zentalis Pharmaceuticals Announces $25 Million Equity Investment From Pfizer
- : Zeno Pharma, LLC
Zentalis Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2022 | Venture | $25.0M |
| Dec 2017 | Venture | Undisclosed |
Leadership
- David Goel, Director
- Karan Takhar, Director
- Cam Gallagher, Executive Officer, Director
- Anthony M.D., Executive Officer, Director
- David Goel, Director
- Karan Takhar, Director
- Cam Gallagher, Executive Officer, Director
- Anthony M.D., Executive Officer, Director
- Aron, Vice President, Investor Relations and Corporate Communications
- Henry, SVP, Head of Intellectual Property
- Jim Bucher, Chief Legal Officer
- Julie Eastland, Chief Executive Officer
Verified email and direct lines for Zentalis Pharmaceuticals’s decision-makers are on Fundz. See plans
Employee benefit plans
Zentalis Pharmaceuticals files 1 employee benefit plan with the U.S. Department of Labor. The next plan year renews in Dec 2026.
Companies similar to Zentalis Pharmaceuticals
- Aquestive Therapeutics, Inc. · Biotechnology, Healthcare, Medical, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Medical, Pharmaceutical, Therapeutics
- Savara Inc · Biotechnology, Healthcare, Medical, Pharmaceutical, Therapeutics
- Nuvalent · Biotechnology, Healthcare, Pharmaceutical, Therapeutics
- Celldex · Biotechnology, Medical, research, Therapeutics
About Zentalis Pharmaceuticals: questions and answers
What does Zentalis Pharmaceuticals do?
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clini
Where is Zentalis Pharmaceuticals headquartered?
Zentalis Pharmaceuticals is headquartered in San Diego, California, United States.
How many employees does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has about 170 employees.
Has Zentalis Pharmaceuticals raised funding?
Yes. Fundz has recorded 2 funding events for Zentalis Pharmaceuticals. The most recent, $25.0M, was in Apr 2022.
Who leads Zentalis Pharmaceuticals?
Aron is a Vice President, Investor Relations and Corporate Communications at Zentalis Pharmaceuticals.
What is the latest news on Zentalis Pharmaceuticals?
On May 21, 2026, SEC 8-K (7.01): On May 21, 2026, Zentalis Pharmaceuticals, Inc. issued a press release reporting important corporate updates which may be of interest to security holders. The specific contents of the release are detailed in Exhibit 99.1 attached to the filing. This Regulation FD Disclosure serves to
Is Zentalis Pharmaceuticals a public company?
Yes. Zentalis Pharmaceuticals is publicly traded under the ticker ZNTL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy